Tarsus Pharmaceuticals agreed to acquire Phase 3 biotech Alkeus Pharmaceuticals for $450 million upfront to expand its ophthalmology pipeline. The transaction adds near-term clinical-phase assets into a category where execution depends on evidence thresholds, manufacturing readiness, and regulatory strategy. The size of the upfront payment signals Tarsus’s intent to build density in vision-related indications and to accelerate its trajectory beyond earlier-stage programs. For Alkeus, the deal provides scale capital and operational bandwidth to advance Phase 3 development toward potential commercialization. Overall, the transaction reflects continued M&A activity in niche ophthalmology—where buyers pay for late-stage de-risking and the right clinical endpoints.